2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2207

Plasma Cytokine Concentrations Are Associated With Folate Perturbations and Methotrexate Polyglutamate Accumulation In The Peripheral Blood Of Juvenile Idiopathic Arthritis Patients Treated With Low-Dose Methotrexate
Abstract Number: 1323

Plasma Leucine-Rich Alpha-2 Glycoprotein Is a Useful Disease Activity Biomarker In Rheumatoid Arthritis
Abstract Number: 733

Plasma Levels Of Fibrin/Fibrinogen Degradation Products Might Be a Useful Indicator Of Disease Activity, Classification and Nephritis Complications In Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Abstract Number: 5

Plasma Levels Of PF-4var/CXCL4L1, A Non Allelic Variant Of Platelet Factor-4 (PF-4/CXCL4), Are Elevated In Patients With Antiphospholipid Syndrome (APS)
Abstract Number: 1747

Plasma MCP-1 and IL-10 Levels Predict Long-Term Progression Of Interstitial Lung Disease In Patients With Early Systemic Sclerosis
Abstract Number: 2516

Plasma Microparticles Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Abstract Number: 297

Plasma Nicotinamide Phosphoribosyltransferase Correlates With Markers Of Inflammation and May Predict Early Therapeutic Response To Low-Dose Methotrexate In Juvenile Idiopathic Arthritis
Abstract Number: 2614

Plasma Of Active Behçet´s Disease Increases Oxidative Metabolism Profile Of Normal and Patients Phagocytes
Abstract Number: 2395

Plasma Short-Talin Is a New Rheumatoid Arthritis Monitoring Biomarker Independent Of The Inflammatory Markers
Abstract Number: 2420

Pleiotropic Roles Of Fcγ Receptors Upregulated On Circulating Monocytes In Rheumatoid Arthritis Patients
Abstract Number: 568

Pneumococcal Polysaccharide Vaccination Regulates T and B Lymphocyte Cytokine Responses and Decreases Kidney Stat1 Levels In MRL/Lpr Mice In Vivo
Abstract Number: 889

Podocytes Take Up Adsdna Autoantibody Complexes
Abstract Number: 1154

Poly(I:C)-Induced Cell Death Of Synovial Fibroblasts via an Unknown dsRNA Receptor
Abstract Number: 1095

Pooled Safety Data From Randomized, Controlled Trials Of Diclofenac Sodium Topical Gel 1% In Subjects With Acute Pain
Abstract Number: 1588

Poor Adherence To Medications For Systemic Lupus Erythematosus Among U.S. Medicaid Beneficiaries

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].